The significance of adiponectin as a biomarker in metabolic syndrome and/or coronary artery disease
Abstract
Background/Aim. Adiponectin exerts profound protective actions during insulin resistence or prediabetes progression towards more severe clinical entities such as metabolic syndrome and/or cardiovascular disease. Since hypoadiponectinaemia contributes to the pathophysiology of the metabolic syndrome and coronary artery disease the level of circulating adiponectin may be an early marker of cardiovascular events. The aim of this study was to determine the relationships between serum adiponectin levels and parameters of both insulin sensitivity and obesity in patients with the metabolic syndrome and/or coronary artery disease, as well as to assess predictive value of adiponectin serum levels as a biomarker of these entitetis. Methods. The study included 100 patients with metabolic syndrome and/or coronary artery disease with different degree of insulin resistance and healthy, normoglycemic individuals. The control group comprising healthy, normoglycemic individuals was used for comparison. Serum level of adiponectin, fasting glucose, fasting insulinemia Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index and anthropometric parameters were determined in all the subjects. Adiponectin was measured by using the ultrasensitive ELISA method. Insulinemia was measured by the radioimmunoassay (RIA) method. The presence of glycemic disorders was assessed on the basis of oral glucose tolerance test (OGTT). Results. Adiponectin level was inversely correlated with age (ρ = - 0.015), parameters of both obesity (R = 0.437; p < 0.001) and insulin resistance (R = 0.374; p < 0.01). Decreasing in the level of adiponectin was strongly implicated in the development of insulin resistance. Most importantly, a statistically significant rapid decrease in adiponectin was in the prediabetic stages (p < 0.01). The predictor value of adiponectin was 1,356.32 ± 402.65 рg/mL. Conclusions. The obtained resultats suggest that adiponectin may be a useful marker in identification of individuals with risk of developing metabolic syndrome and coronary artery disease, as well as a predictor of prediabetes.
References
Boydens C, Maenhaut N, Pauwels B, Decaluwé K, van de Voorde J. Adipose tissue as regulator of vascular tone. Curr Hypertens Rep 2012; 14(3): 270−8.
Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121(6): 2111−7.
Lago F, Gómez R, Gómez-Reino JJ, Dieguez C, Gualillo O. Adi-pokines as novel modulators of lipid metabolism. Trends Bio-chem Sci 2009; 34(10): 500−10.
Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316(2): 129−39.
Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, et al. Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. PLoS Genet 2012; 8(3): 1002607.
Comuzzie AG, Funahashi T, Sonnenberg G, Martin LJ, Jacob HJ, Black AE, . The genetic basis of plasma variation in adiponec-tin, a global endophenotype for obesity and the metabolic syndrome. J Clin Endocrinol Metab 2001; 86(9): 4321−5.
Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardio-vascular health: an update. Br J Pharmacol 2012; 165(3): 574−90.
Cheng KK, Lam KS, Wang B, Xu A. Signaling mechanisms un-derlying the insulin-sensitizing effects of adiponectin. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 3−13.
Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: les-sons from translational research. Am J Clin Nutr 2010; 91(1): 258−61.
Aronne LJ, Segal KR. Adiposity and Fat Distribution Outcome Measures: Assessment and Clinical Implications. Obes Res 2002; 10(1): 14−21.
World Health Organization. Definition, diagnosis and classifica-tion of diabetes mellitus and its complications, Part 1: Diagno-sis and classification of diabetes mellitus. Geneva: Department of Noncommunicable Disease Surveillance; 1999.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412−9.
Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, García F, De Francisco A, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 2013; 13(1): 47.
RND sistems. Human Adiponectin/Acrp30 DuoSet. Available from: http://www.rndsystems.com/Products/DY1065.
Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148(5): 852−71.
Saely CH, Risch L, Hoefle G, Rein P, Muendlein A, Marte T, et al. Low serum adiponectin is independently associated with both the metabolic syndrome and angio-graphically determined coronary atherosclerosis. Clin Chim Acta 2007; 383(1−2): 97−102.
Luo S, Lei H, Liu Q. Correlation between serum adiponectin and risk factors in patients with coronary artery disease. Clin Lab 2013; 59(1−2): 121−6.
Oliveira GB, França JÍ, Piegas LS. Serum adiponectin and cardi-ometabolic risk in patients with acute coronary syndromes. Arq Bras Cardiol 2013; 101(5): 399−409.
Wang Y, Lam K , Yau M, Xu A. Post-translational modifica-tions of adiponectin: mechanisms and functional implications. Biochem J 2008; 409(3): 623−33.
Kim JY, Choi EY, Mun HS, Min PK, Yoon YW, Lee BK, et. al. Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity ccording to the presence of diabetes mellitus: relation with inflammatory markers and adipokines. Cardiovasc Diabetol 2013; 12: 140.
Indulekha K, Surendar J, Anjana RM, Gokulakrishnan K, Bal-asubramanyam M, Aravindhan V, et al. Circulating levels of high molecular weight (HMW) adiponectin and total adiponectin in relation to fat distribution, oxidative stress and inflammation in Asian Indians. Dis Markers 2012; 33(4): 185−92.
Medina-Bravo P, Meza-Santibáñez R, Rosas-Fernández P, Galván-Duarte R, Saucedo-García R, Velázquez-López L, et al. Decrease in serum adiponectin levels associated with visceral fat accumula-tion independent of pubertal stage in children and adolescents. Arch Med Res 2011; 42(2): 115−21.
Hajer GR, van Haeften TW, Visseren F. Adipose tissue dysfunc-tion in obesity, diabetes and vascular diseases. Europ Heart J 2008; 29(24): 2959−71.
Trayhurn P, Bing C, Wood S. Adipose Tissue and Adipokines-Energy Regulation from the Human Perspective. J Nutr 2006; 136(7): 1935−9.
Shams M, Rasekhi Kazerouni A, Ostovan MA, Omrani GR. The re-lationship between serum adiponectin levels with the presence and severity of coronary artery disease. Arch Iran Med 2012; 15(10): 611−6.
Golubović MV, Dimić D, Antić S, Radenković S, Djindjić B, Jovanović M. Relationship of adipokine to insulin sensitivity and glycemic regulation in obese women - the effect of body weight reduction by caloric restriction. Vojnosanit Pregl 2013; 70(3): 284−91. (Serbian)
Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K, et al. Association of low adiponectin levels with the metabolic syndrome-the Chennai Urban Rural Epidemiol-ogy Study (CURES-4). Metabolism 2005; 54(4): 476−81.
Shahid A, Sager A, Muhammad FM, Syed DH, Kiran N, Muham-mad SH. Role of adiponectin as a biomarker of prediabetes. Med Channel 2012; 18(4): 72−5.